Suppr超能文献

CD4 + T细胞在恶病质控制中的新作用。

A novel role for CD4+ T cells in the control of cachexia.

作者信息

Wang Zhuangzhi, Zhao Chunfang, Moya Rosa, Davies Joanna D

机构信息

Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA.

出版信息

J Immunol. 2008 Oct 1;181(7):4676-84. doi: 10.4049/jimmunol.181.7.4676.

Abstract

Cachexia is the dramatic weight loss and muscle atrophy seen in chronic disease states, including autoimmunity, cancer, and infection, and is often associated with lymphopenia. We have previously shown that CD4(+) T cells that express the lowest density of CD44 (CD4(+)CD44(v.low)) are significantly reduced in diabetic NOD mice that are cachexic compared with diabetic mice that are not cachexic. Using this model, and a model of cancer cachexia, we test the hypothesis that CD4(+)CD44(v.low) cells play an active role in protecting the host from cachexia. CD4(+)CD44(v.low) cells, but not CD4(+) cells depleted of CD44(v.low) cells, delay the onset of wasting when infused into either diabetic or prediabetic NOD recipients. However, no significant effect on the severity of diabetes was detected. In a model of cancer cachexia, they significantly reduce muscle atrophy, and inhibit muscle protein loss and DNA loss, even when given after the onset of cachexia. Protection from wasting and muscle atrophy by CD4(+)CD44(v.low) cells is associated with protection from lymphopenia. These data suggest, for the first time, a role for an immune cell subset in protection from cachexia, and further suggest that the mechanism of protection is independent of protection from autoimmunity.

摘要

恶病质是在慢性疾病状态下出现的显著体重减轻和肌肉萎缩,包括自身免疫性疾病、癌症和感染,且常与淋巴细胞减少有关。我们之前已经表明,与无恶病质的糖尿病NOD小鼠相比,患有恶病质的糖尿病NOD小鼠中表达最低密度CD44的CD4(+) T细胞(CD4(+)CD44(v.low))显著减少。利用这个模型以及癌症恶病质模型,我们检验了CD4(+)CD44(v.low)细胞在保护宿主免受恶病质影响方面发挥积极作用的假说。当将CD4(+)CD44(v.low)细胞而非耗尽CD44(v.low)细胞的CD4(+)细胞注入糖尿病或糖尿病前期的NOD受体时,可延迟消瘦的发生。然而,未检测到对糖尿病严重程度的显著影响。在癌症恶病质模型中,即使在恶病质发作后给予这些细胞,它们也能显著减轻肌肉萎缩,并抑制肌肉蛋白质损失和DNA损失。CD4(+)CD44(v.low)细胞对消瘦和肌肉萎缩的保护作用与对淋巴细胞减少的保护作用相关。这些数据首次表明了一种免疫细胞亚群在保护机体免受恶病质影响方面的作用,并且进一步表明保护机制独立于对自身免疫的保护作用。

相似文献

1
A novel role for CD4+ T cells in the control of cachexia.
J Immunol. 2008 Oct 1;181(7):4676-84. doi: 10.4049/jimmunol.181.7.4676.
2
Cachexia in the non-obese diabetic mouse is associated with CD4+ T-cell lymphopenia.
Immunology. 2008 Sep;125(1):48-58. doi: 10.1111/j.1365-2567.2008.02819.x. Epub 2008 Apr 4.
3
A peripheral CD4+ T cell precursor for naive, memory, and regulatory T cells.
J Exp Med. 2010 Dec 20;207(13):2883-94. doi: 10.1084/jem.20100598. Epub 2010 Dec 13.
4
6
Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development.
J Immunol. 2003 Oct 15;171(8):4040-7. doi: 10.4049/jimmunol.171.8.4040.

引用本文的文献

1
Immune System Disorder and Cancer-Associated Cachexia.
Cancers (Basel). 2024 Apr 27;16(9):1709. doi: 10.3390/cancers16091709.
2
R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice.
J Cachexia Sarcopenia Muscle. 2024 Apr;15(2):562-574. doi: 10.1002/jcsm.13422. Epub 2024 Feb 1.
3
CD4+ T cells regulate sickness-induced anorexia and fat wasting during a chronic parasitic infection.
Cell Rep. 2023 Aug 29;42(8):112814. doi: 10.1016/j.celrep.2023.112814. Epub 2023 Jul 24.
4
Cancer cachexia: molecular mechanisms and treatment strategies.
J Hematol Oncol. 2023 May 22;16(1):54. doi: 10.1186/s13045-023-01454-0.
5
Immunoregulation in cancer-associated cachexia.
J Adv Res. 2024 Apr;58:45-62. doi: 10.1016/j.jare.2023.04.018. Epub 2023 May 6.
6
Progressive development of melanoma-induced cachexia differentially impacts organ systems in mice.
Cell Rep. 2023 Jan 31;42(1):111934. doi: 10.1016/j.celrep.2022.111934. Epub 2022 Dec 29.
7
Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene.
Front Cell Dev Biol. 2022 Sep 8;10:960341. doi: 10.3389/fcell.2022.960341. eCollection 2022.
8
Targeting cancer cachexia: Molecular mechanisms and clinical study.
MedComm (2020). 2022 Sep 10;3(4):e164. doi: 10.1002/mco2.164. eCollection 2022 Dec.
9
Pathological features of tissues and cell populations during cancer cachexia.
Cell Regen. 2022 Apr 20;11(1):15. doi: 10.1186/s13619-022-00108-9.

本文引用的文献

2
Cachexia in the non-obese diabetic mouse is associated with CD4+ T-cell lymphopenia.
Immunology. 2008 Sep;125(1):48-58. doi: 10.1111/j.1365-2567.2008.02819.x. Epub 2008 Apr 4.
3
Possible mechanisms underlying the development of cachexia in COPD.
Eur Respir J. 2008 Mar;31(3):492-501. doi: 10.1183/09031936.00074807.
4
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.
Nutrition. 2008 Apr;24(4):305-13. doi: 10.1016/j.nut.2007.12.010. Epub 2008 Feb 11.
5
Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients.
Clin Nutr. 2007 Oct;26(5):614-8. doi: 10.1016/j.clnu.2007.06.005. Epub 2007 Aug 3.
6
Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis.
J Exp Med. 2007 Jul 9;204(7):1665-75. doi: 10.1084/jem.20070618. Epub 2007 Jun 25.
7
Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia.
Clin Nutr. 2007 Aug;26(4):389-99. doi: 10.1016/j.clnu.2007.03.008. Epub 2007 May 11.
8
Symptom control trials: a 20-year experience.
J Support Oncol. 2007 Mar;5(3):119-25, 128.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验